Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773769 | 0.93 | PTGDR2 (0.53) | PTGDR2FFAR1GAA | |
| SCHEMBL2771517 | 0.91 | PTGDR2 (0.51) | PTGDR2FFAR1GAAHTT | |
| SCHEMBL2773044 | 0.91 | PTGDR2 (0.58) | PTGDR2FFAR1GAANPC1RAB9A | |
| SCHEMBL2771361 | 0.91 | ALDH1A1 (0.47) | PTGDR2FFAR1GAAALDH1A1 | |
| SCHEMBL2772793 | 0.90 | PTGDR2 (0.44) | PTGDR2FFAR1GAANR3C2USP2 | |
| SCHEMBL2772839 | 0.89 | FFAR1 (0.49) | PTGDR2FFAR1GAANR3C2 | |
| SCHEMBL2772207 | 0.89 | PTGDR2 (0.56) | PTGDR2FFAR1NR3C2LMNARAB9A | |
| SCHEMBL2771467 | 0.87 | ACLY (0.47) | PTGDR2FFAR1GAANR3C2 | |
| SCHEMBL2770349 | 0.85 | SMN1; SMN2 (0.47) | PTGDR2FFAR1GAANR3C2 | |
| SCHEMBL2771014 | 0.85 | PTGDR2 (0.48) | PTGDR2FFAR1GAANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | claimed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | claimed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | HSD17B12, CYP2A13, CYP27A1 | PTGDR2 377/4885FFAR1 213/4885GAA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.